NIH SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional): PAR-27-098

NIH SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional): PAR-27-098

Key details

What this opportunity is designed to support

PAR-27-098 is a NIH parent funding track meant to handle a narrow but very practical gap in SBIR/STTR commercialization. The NOFO describes it as support for later-stage R&D and/or technical assistance needed after earlier SBIR or STTR milestones. In simple terms, this is for small businesses that already cleared the feasibility and implementation phases and now need additional evidence, technical work, quality systems, or external expertise to move toward commercialization.

The full announcement explicitly says the program supports activities NIH Phase II and Phase IIB recipients usually do not get funded under those existing mechanisms, including:

• independent replication or confirmation of key studies,
• IND/IDE-enabling work,
• additional late-stage clinical studies,
• manufacturing scale-up and quality-related work,
• regulatory and technical commercialization support,
• and other specialized technical assistance (for example market research).

This is not a first-in-cycle grant for discovery concepts. It is a bridge mechanism. It is also broader than a normal Phase I/II SBIR grant in that it explicitly allows a significant amount of outsourcing for specific commercialization tasks, including contractual technical support where that is the most efficient way to remove barriers.

The program is useful if the project is currently blocked by a nonlinear commercialization step: strong science exists, but investors or manufacturing/regulatory plans are stalling progress.

Why PAR-27-098 matters in a 2026/2027 planning cycle

The NOFO was posted in 2026 and has recurring NIH standard submission dates. Its calendar includes multiple annual cycles after the initial opening:

• September 5 (2026 onward),
• January 5,
• April 5,

with repeated rounds extending into 2029 as shown in the published key date table. That is important for planning: there is usually another opening window in the coming months, so teams that miss September can still align to later quarterly dates.

Because the award is a parent mechanism, it is not tightly limited to one niche topic. The requirement is that activities fit participating component mission areas and that the proposed commercialization pathway is credible and executable.

Eligibility profile: who should apply, and who should not

The NOFO has the strongest entry rule: this is primarily for U.S. small business concerns (with additional applicant classes listed on the listing page, but with core language centered on SBC pathways).

For this program to be a realistic fit, the project should satisfy all of the following practical criteria:

1. The team can show a prior qualifying NIH SBIR or STTR lifecycle foundation (the NOFO focuses on follow-on work from NIH SBIR/STTR Phase II and/or strategic breakthrough track progress).
2. The business has a real commercialization bottleneck that requires funded technical help or late-stage development.
3. The work is mission-relevant to one or more participating NIH components.
4. The applicant is willing to complete all required federal registrations before submission.
5. The proposal can defend that planned activities move from “promising development” to investible proof.

Important policy guardrails:

• The NOFO does not permit foreign entities as submitting organizations.
• Foreign subawards/subcontracts are treated as noncompliant in most contexts for this NOFO and are generally disallowed unless specifically exempted by policy.
• Not every participating NIH component accepts every activity type equally, including clinical trials. Your route should include a compatibility check against mission guidance and applicable IC expectations.
• This is not a free-form innovation grant. It is conditioned on prior NIH small-business traction, so pure pre-award discovery teams should usually start with PA-27-100 or PA-27-102 as the right entry channel.

Relationship to other NIH SBIR/STTR instruments

The NOFO itself positions PAR-27-098 in relation to nearby instruments. In practice:

• PA-27-100 handles fresh SBIR Phase I/II and direct-to-phase-II NIH SBIR entry.
• PA-27-101 covers Strategic Breakthrough for late-stage SBIR Phase IIB commercialization support with specific matching requirements and limits.
• PA-27-102 is the STTR parent path for projects requiring nonprofit collaboration.

PAR-27-098 fills a different position: the commercialization readiness gap where teams need structured help after those mechanisms but before independent commercialization can continue without NIH bridge support.

This positioning also affects application strategy: if reviewers perceive your proposal as simply a delayed Phase II resubmission with no clearly identified readiness gap, it can fail on competitiveness.

What PAR-27-098 actually funds

The NOFO language frames activities into two buckets, both of which must be clearly justified:

A) Technical assistance

Examples listed by the NOFO include:

• regulatory strategy support,
• IP strategy support,
• manufacturing technical help,
• outsourced market-research support.

Technical assistance should not be generic consulting. It needs to be tightly linked to commercialization milestones and the value inflection point.

B) Late-stage R&D

Examples include:

• independent confirmation studies,
• development of manufacturing and quality systems,
• clinical or preclinical work when justified,
• activities intended to reduce investor or partnership risk.

A strong PAR-27-098 proposal usually frames each proposed task as one of these concrete outputs that can be tracked and used to unlock private follow-on funding or partnerships.

Timeline and deadlines you can plan around

As published:

• Posted: May 28, 2026
• Open: August 05, 2026
• Standard cycle dates include September 05, 2026 and continuing quarterly
• Expiration: April 06, 2029

Given this date grid, this is an opportunity to monitor and time your submission:

• If you are in development this spring, September 2026 is your first realistic cycle.
• If internal approvals are incomplete, January or April cycle may still be viable.
• If you are building evidence for investors, use early feedback to align one-quarter later than your first planned cycle.

The NOFO also emphasizes no late applications are accepted and due time is local organization time at 5:00 PM.

Application preparation checklist (practical sequence)

1) Confirm pathway fit early

The first week of prep should be eligibility confirmation:

• Confirm your prior NIH award status and whether your proposed follow-on project is a valid CRP continuation of prior commercialization need.
• Confirm that your planned activities are not better suited to PA-27-101 (strategic breakthrough route), PA-27-100, or PA-27-102.
• Confirm participating IC compatibility and whether your component accepts the type of trial or study you propose.
• Review NIH eligibility criteria and prior-application history constraints in the NOFO.

2) Complete registrations before budget drafting

The NOFO requires standard federal registrations before submission:

• SAM (with UEI / CAGE workflow),
• SBA company registration where applicable,
• eRA Commons PI linkage,
• Grants.gov registration (direct or via institutional systems).

The page for this opportunity explicitly warns that registration should be done early and may take several weeks.

3) Build the commercialization plan around a specific barrier

The Commercialization Plan section is not decorative. It should answer:

• what exactly is the key commercialization risk,
• what activity funded by CRP reduces that risk,
• what objective evidence will be produced,
• what is the timeline from CRP completion to third-party funding/strategic partnership or commercialization progression,
• and where internal execution ends versus outsourced execution begins.

Because CRP activities are expected to be highly execution-focused, weak narrative without measurable outputs is usually heavily penalized.

4) Use the correct application workflow and forms

Applicants can use NIH ASSIST, institutional S2S, or Grants.gov Workspace routes as allowed. Ensure the application type is set to the CRP program and that instructions are not mixed with standard SBIR/STTR defaults that can cause compliance issues.

5) Be explicit about outsourcing and service quotes

The NOFO allows significant outsourcing in CRP projects and explicitly suggests budget justification for external work. Include concrete quotes and a realistic budget split for outsourced vs in-house activities.

Review lens and common success factors

The NOFO’s review framework places emphasis on whether the proposal actually moves commercialization readiness and strengthens outside investment potential. Reviewers evaluate:

• feasibility and quality of planned commercialization bridge tasks,
• whether proposed activities address prior evidence gaps,
• quality of prior work to justify continuation,
• and whether outputs are achievable in CRP timeline and budget scope.

You should therefore write the narrative around outcomes, not around interesting but non-decisive work. If your proposal reads like “interesting science,” it will be weaker than one that reads like “this specific work will produce X and unlock Y investor/partner signal.”

Also pay attention to review sections often overlooked:

• commercialization history and prior progress,
• human subjects and clinical inclusion sections (where relevant),
• security and management plan alignment,
• compliance with appendix limitations,
• and any special data/resource sharing constraints.

Common mistakes to avoid

Mistake 1: Treating CRP like a PI-first or discovery call

This opportunity is not where you should start from a raw hypothesis. It is post-Phase II commercialization infrastructure support.

Mistake 2: Submitting without a clear prior SBIR/STTR linkage

The NOFO explicitly ties participation to prior SBIR/STTR pipeline context. If that is fuzzy, address the link first in your eligibility section.

Mistake 3: Weak commercialization milestones

Reviewers expect a realistic path to investment, regulatory traction, or commercialization progress. Vague wording (“we will explore commercialization”) is weak.

Mistake 4: Ignoring incompatibilities

Some components or activity types are not accepted under specific conditions. You should map each work package to participating IC mission fit before final submission.

Mistake 5: Not including required registrations and PI setup

Late registration is a recurring failure mode. Build registration as a gating task with ownership and deadlines.

Mistake 6: Overlooking no-cost sharing and cost-sharing assumptions

The NOFO states no required matching, but full commercialization is still expected to continue with non-SBIR funds after award. Plan your next funding layer accordingly.

After the award: what happens if you win

If funded, this is still a federal award with standard NIH reporting terms and federal accountability. This includes post-award monitoring, final reporting requirements, and compliance obligations across cyber, privacy, equal opportunity, and federal assistance terms.

A practical expectation from awarded teams:

• integrate outputs into a measurable commercialization timeline,
• maintain records for outsourced service outcomes,
• keep commercialization claims tied to verifiable milestones,
• and prepare for RPPR/financial reporting at required checkpoints.

You also need to align any planned technical assistance with budgeted actions and ensure nothing in execution conflicts with post-award security/cyber obligations.

Official links and best place to verify current status

• Opportunity listing (official NIH/Grants aggregation): https://simpler.grants.gov/opportunity/ed6db6b2-d74e-4838-9223-ce72f4895688
• Full announcement (official PDF-backed text): https://files.simpler.grants.gov/opportunities/ed6db6b2-d74e-4838-9223-ce72f4895688/attachments/499e5c34-2366-47af-911c-49e42d8e5afd/PAR-27-098-Full-Announcement.html
• NIH SBIR/STTR overview and related pathways: https://seed.nih.gov/small-business-funding/find-funding/sbir-sttr-funding-opportunities

FAQ

Is PAR-27-098 a recurring opportunity?

Yes. The published NOFO contains multiple standard NIH due dates over several years, not a single one-off cycle.

Is this for first-time SBIR teams only?

No. It is specifically focused on follow-on commercialization-readiness work tied to prior Phase II or Phase IIB contexts.

Can non-small-business entities apply?

The primary intended track is small business concerns. The NOFO also references additional entity categories but the core CRP flow is designed for SBC-driven commercialization execution. Use the official NOFO text as final authority for your case.

Is there cost sharing?

The NOFO states no cost sharing requirement.

Is this an option for clinical-trial-heavy projects?

Clinical research can be included, but each NIH component has specific considerations. Confirm component compatibility before submission.